

REMARKS

In response to the Restriction Requirement electronically delivered on November 19, 2007, Applicants elect without traverse to prosecute the claims in Group I, namely Claims 1-23, drawn to a method of treatment. In response to the requirement to elect a single disclosed species for prosecution, Applicants provisionally elect 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl as the single specific chemically defined nitroxide compound species; surgery as the single specific medical procedure species; intravenous administration as the single specific route of administration; and the method of Claim 1 as the single specific method species wherein the method steps are specifically defined. Claims 1-23 read on the elected species. As noted by the Examiner, upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to the additional species which depend from or otherwise require all the limitations of an allowable generic claims as provided by 37 CFR 1.141. The Examiner notes that Claims 1 and 9 are considered generic to the elected species (*see*, page 4 of the Restriction Requirement). Claims 24-31 have been cancelled without prejudice to further prosecution in a subsequently filed divisional or continuation application.


Applicants submit that the present Application is in condition for examination on the merits and respectfully request the same. If any issues remain with respect to the restriction requirement, the Examiner is cordially invited to contact Applicants' representative at the number provided below in order to resolve such issues promptly.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12-19-2007

By: 
Susan L. Wang, Ph.D.
Registration No. 53,742
Attorney of Record
Customer No. 20,995
(415) 954-4114